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SSSS had positive anti-Dsg1 IgG by
ELISA as well as immunoblotting,
although serum was obtained only at
day 6 (SSSS no. 6 in Table 2). No anti-
Dsg3 IgG was detected either by ELISA
or by immunoblotting in these patients
studied throughout their course, indi-
cating the specificity of the reactivity
against Dsg1 (Table 1). No apparent
IgM reactivity against Dsg1 or Dsg3
was detected by ELISA (data not
shown). None of the 12 patients with
BI, whose sera were taken with a range
of days 2–33, showed any detectable
IgG production against either Dsg1 or
Dsg3 as determined by ELISA and
immunoblotting (Table 1).
These findings indicate that a small
number of patients of SSSS develop low
titers of IgG antibodies specific for Dsg1
after binding and systemic digestion of
Dsg1 by staphylococcal ETs. This ob-
servation is specific for patients with
SSSS because none of the patients with
BI showed any sign of anti-Dsg1 anti-
body production. This may be because
a single episode of BI may be too
limited to cause an immune response.
Although none of these patients devel-
op PF after SSSS, which is not known as
a predisposing factor for PF, the findings
presented here provide evidence that
infection which modifies self-antigen
can trigger the production of IgG
autoantibodies against the self-antigen.
Of course, these patients do not devel-
op clinically overt PF. We would
speculate that other genetic or environ-
mental factors are needed to extend the
immune response to encompass patho-
genic antibodies and to produce overt
clinical PF. For example, in the endemic
form of PF, fogo selvagem, that is found
in rural areas of South America, it might
be possible that repeated modification of
Dsg1 by chronic or recurrent staphylo-
coccal infection in genetically suscepti-
ble individuals might trigger disease.
Thus, our data are consistent
with the hypothesis that a bacterial
toxin can modify a self-antigen to result
in an autoantibody response. The re-
levance of this finding to onset of
autoimmune diseases remains to be
proven.
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TO THE EDITOR
Atopic dermatitis (AD) is one of the
most common inflammatory skin dis-
orders characterized by pruritus, a
chronically relapsing course and typi-
cally distributed lesions with dry skin,
excoriations, and lichenification (Leung
et al., 2004). Topical treatment of acute
lesions with corticosteroids (CS) is a
mainstay in the therapy of the AD;
however, long-term application is limi-
ted by CS-related side effects (e.g., skin
atrophy) (Stoppolino et al., 1983). The
calcineurin inhibitors tacrolimus and
pimecrolimus are now available as
ointment/cream preparations and have
proven to be a novel option for the
topical treatment of AD (Ruzicka et al.,
1997; Luger et al., 2001).
AD skin lesions harbor a variety of
inflammatory cells, of which dendritic
cells (DCs) represent a major fraction.
Besides resident Langerhans cells and
inflammatory dendritic epidermal cells,
Abbreviations: AD, atopic dermatitis; BMV, beta-methasone-17-valerate; CS, corticosteroids;
DC, dendritic cell; MFI, mean fluorescence intensity; pDC, plasmacytoid DC
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the presence of plasmacytoid DC (pDC)
has recently been demonstrated in the
dermis and less abundant in the epi-
dermis of AD lesions (Wollenberg et al.,
2002; Hashizume et al., 2005). pDC
are characterized by a plasma-cell-like
morphology, a unique surface pheno-
type (HLA-DRþCD1aCD123þBDCA-
2þFceRIþ ), and the ability to produce
large amounts of IFN-a, which assigns
them a key role in innate antiviral
immunity (Cella et al., 1999; Siegal
et al., 1999).
In prior studies, we have investigated
the impact and mode of action of CS
and pimecrolimus on the DC popula-
tion in murine and healthy human and
lesional AD skin and have reported
divergent effects of these compounds
on Langerhans cell viability and func-
tion (Hoetzenecker et al., 2004, 2005).
In light of this finding, we asked
whether these compounds also affect
pDC. For this purpose, skin biopsies
from a previous clinical trial were
utilized (Hoetzenecker et al., 2005).
Briefly, 22 patients suffering from AD
according to the diagnostic criteria of
Hanifin and Rajka (Hanifin and Rajka,
1980; Rajka and Langeland, 1989) were
assigned to treatment with 1% pime-
crolimus cream (eight patients), match-
ing vehicle cream (six patients), or
0.1% beta-methasone-17-valerate
((BMV), eight patients) in a 3-week,
randomized, double-blind, vehicle-
controlled parallel-group clinical trial.
Creams were applied twice daily to all
affected areas of the skin (except face)
and punch biopsies (4 mm) were taken
from acute lesions before treatment
(day 0; begin of study) and on day 21
(end of study) after initiation of therapy.
The study was conducted according to
the guidelines of the Declaration of
Helsinki Principles, approved by the
local ethics committee of the Medical
University of Vienna (code numbers:
EK303/2003 and EK355/2005) and a
written informed consent was obtained
from all patients. Immunoperoxidase
staining against the pDC-specific mar-
ker BDCA-2 revealed substantial pDC
numbers in the dermis of untreated AD
skin lesions (3378 cells/mm2 dermis;
n¼22), whereas pDC in normal
healthy control skin were essentially
absent (data not shown; n¼5). As
shown in Figure 1, topical treatment
with pimecrolimus and BMV for 21
days caused an almost complete dis-
appearance of skin-infiltrating BDCA-
2þ cells by 94 and 95%, respectively,
in comparison to vehicle-treated skin.
The disappearance of BDCA-2þ cells
can be due to either the loss/down-
regulation of this marker on the respon-
der cell or due to actual deletion/
destruction of pDC. In order to address
this issue, pDC were isolated from
peripheral blood of healthy adult vo-
lunteers (Figure 2a) and cultured with
pimecrolimus and BMV at a concentra-
tion of 106 mol/l (Figure 2b). We have
chosen this concentration intending to
use the highest, non-toxic, biologically
relevant dose for pimecrolimus to see
an effect (Grassberger et al., 1999;
Kalthoff et al., 2003). At selected time
points, cells were analyzed for marker
expression and viability. Neither pime-
crolimus nor BMV downmodulated the
expression of BDCA-2 on pDC at any
time point investigated (Figure 2b).
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Figure 1. Topical treatment with pimecrolimus and BMV significantly depletes BDCA-2þ cells in AD skin lesions. Cryostat sections (5mm) were air-dried and
fixed in ice-cold acetone for 10 minutes. To prevent nonspecific binding of the anti-BDCA-2 mAb (Miltenyi Biotec Inc., Auburn, CA), it was mixed with
1% normal horse serum and 2% BSA and applied to sections (1 hour, room temperature). Immunolocalization of the primary antibody was performed using
a biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA), followed by an avidin-biotinylated-HRP third layer (Vector Laboratories).
AECþ substrate (DakoCytomation, Glostrup, Denmark) were used as chromogen and sections were counterstained with Gill’s hematoxylin (Santa Cruz
Biotechnologies, Santa Cruz, CA). In all staining experiments, an IgG1 isotype mAb served as negative control. Representative pictures of immunostained
sections were taken and positive cells are marked by arrows (upper panels). pDC numbers were evaluated in a blinded fashion (25–45 counted fields per section
under  25 object lenses; numbers of patients per group: untreated¼ 22, vehicle control¼ 6, pimecrolimus¼8, BMV¼ 8) by two independent investigators and
results are expressed as mean7SEM positive cells/mm2 dermis. One-way analysis of variance was used to evaluate statistically significant differences between
test and control groups. *Po0.05 versus control. Bars¼200 mm.
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However, we observed a marked re-
duction of BDCA-2þ cells on BMV
(92%), but not pimecrolimus (24%)
culture already after 2 days when
compared to vehicle (21%) (Figure
2c). After 7 days, pimecrolimus did
not alter the viability of pDC when
compared to vehicle (Figure 2c). In
contrast, pDC on BMV culture were all
dead at this time point (not shown).
From these data, we conclude that the
disappearance of BDCA-2þ cells in AD
lesions upon CS treatment most likely
results from a depletion of pDC. The
mechanism responsible for their deple-
tion in vivo remains to be investigated.
In keeping with recent reports from
others (Shodell et al., 2003; Suda et al.,
2003; Abe and Thomson, 2006), our
data suggest that the reduction of pDC
after topical treatment with CS may be
owing to apoptosis. With regard to
pimecrolimus, we have no evidence
for direct effect on apoptosis in pDC in
contrast to CS treatment. Theoretical
possibilities are that indirect mechan-
isms such as cell migration and/or
withdrawal of cytokines owing to an
apoptosis-induced depletion of T cells
upon pimecrolimus treatment (Hoetze-
necker et al., 2005) may be responsible
for their depletion.
It is well known that patients with
AD have recurrent bacterial or viral
skin infections. The reason for this
particular susceptibility is not entirely
understood. Recent evidence exists that
these individuals have a defect in the
production of natural antimicrobial
peptides (Ong et al., 2002; Rieg et al.,
2005). Another reason could be a
defect in other elements of the innate
immune system. Indeed, pDC are less
abundant in the infiltrate of AD lesions
as compared to allergic contact eczema
(Wollenberg et al., 2002; Bangert et al.,
2003; Stary et al., 2005). It will be
interesting to see whether a functional
defect of pDC may contribute to the
high susceptibility of these patients to
skin infections.
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Figure 2. CS but not pimecrolimus strongly reduce pDC numbers in vitro. Buffy coats from peripheral
blood of healthy adult volunteers were purchased from the local transfusion service (Rotes Kreuz, Vienna,
Austria). Peripheral blood monocytes were isolated as interface cells after density gradient centrifugation
(Lymphoprep; Axis-Shield, Rodelokka, Norway) and erythrocytes were removed with ammonium
chloride (0.8% NH4Cl/0.1 mM EDTA). pDC (mean purity: 93.88%75.21 (n¼4)) were isolated using a
negative isolation kit according to the manufacturer’s manual (Miltenyi Biotec Inc.). (a) Freshly isolated
cells were stained for the indicated markers and 30,000 events/sample were acquired. pDC were cultured
(5106/ml) for the indicated time periods (day 2: n¼3; day 7: n¼ 1) in RPMI 1640 medium (GIBCO
Life Technologies, Carlsbad, CA) supplemented with 10% FCS, 2 mM L-glutamine, antibiotics, and 10 ng/
ml recombinant human IL-3 (Pepro Tech, Rocky Hill, NJ) in the presence of vehicle, pimecrolimus, or
BMV (all 106 mol/l). Fluorescence was measured with a FACSCalibur flow cytometer, and data were
analyzed using Cell Quest software (both Becton Dickinson, San Jose, CA). (b) Mean fluorescence
intensity (MFI) was determined for BDCA-2 expression and (c) dead cells were identified by
7-amino-actinomycin D uptake (Sigma Chemicals Co., St Louis, MO).
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